Emergent BioSolutions Inc (EBS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
- Business description - A detailed description of the company’s operations and business divisions.
- Corporate strategy - Analyst’s summarization of the company’s business strategy.
- SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history - Progression of key events associated with the company.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of the company.
- Executive biographies - A brief summary of the executives’ employment history.
- Key operational heads - A list of personnel heading key departments/functions.
- Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
Emergent BioSolutions Inc (Emergent) is a life sciences company that provides specialized products to address medical needs and public health threats (PHTs). Its solutions help address PHTs including chemical, biological, radiological, travel health, emerging health crises, nuclear and explosives (CBRNE), emerging infectious diseases and acute/emergency care. It offers vaccines, therapeutics, drug-device combination products, and contract development and manufacturing services. Emergent's pipeline candidates target dengue and other influenza infections. It also offers specialized products to governments and commercial customers. The company distributes its products in the US and Canada through its commercial sales forces and third-party distributors. Emergent is headquartered in Rockville, Maryland, the US.Emergent BioSolutions Inc Key Recent Developments
- Apr 19, 2023: Emergent BioSolutions to release first quarter 2023 financial results and conduct conference call on May 9, 2023
- Feb 27, 2023: Emergent BioSolutions Reports Financial Results for Fourth Quarter 2022
- Feb 06, 2023: Emergent BioSolutions to Release Fourth Quarter 2022 Financial Results and Conduct Conference Call on February 27, 2023
- Nov 08, 2022: Emergent BioSolutions Reports Financial Results For Third Quarter 2022
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Table of Contents
Section 1 - About the Company
Section 2 - Company Analysis
Section 3 - Company Financial Ratios
Section 4 - Company’s Lifesciences Financial Deals and Alliances
Section 5 - Company’s Recent Developments
Section 6 - Appendix
List of Tables
List of Figures
Samples
LOADING...
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Elusys Therapeutics Inc
- Merck & Co Inc
- Genentech USA Inc
- Intralytix Inc
- Soligenix Inc
- GC Biopharma Corp
- GSK plc
- Novartis AG
- Greffex Inc
- Hikma Pharmaceuticals USA Inc
- Amgen Inc
- Altimmune Inc
- Altimmune Inc
- Amgen Inc
- Amphastar Pharmaceuticals Inc
- Elusys Therapeutics Inc
- GC Biopharma Corp
- Genentech USA Inc
- Greffex Inc
- GSK plc
- Hikma Pharmaceuticals USA Inc
- Intralytix Inc
- Merck & Co Inc
- Mitsubishi Tanabe Pharma Corp
- Teva Pharmaceutical Industries Ltd
- Soligenix Inc
- SIGA Technologies Inc
- Novartis AG
- SIGA Technologies Inc
- Mitsubishi Tanabe Pharma Corp
- Teva Pharmaceutical Industries Ltd
- Amphastar Pharmaceuticals Inc